BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Canadian Pulmonary Fibrosis Foundation - ECPv6.17.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://cpff.ca
X-WR-CALDESC:Events for Canadian Pulmonary Fibrosis Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250904T140000
DTEND;TZID=America/Toronto:20250904T150000
DTSTAMP:20250806T145509Z
CREATED:20250805T195338Z
LAST-MODIFIED:20250806T145509Z
UID:10001356-1756994400-1756998000@cpff.ca
SUMMARY:Nerandomilast in IPF and PPF: A New Option On the Horizon
DESCRIPTION:Featuring: Dr. Shane Shapera \n\n\n\nThere is a new pulmonary fibrosis medication called Nerandomilast that is currently undergoing government approval processes as a treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). In this online webinar\, Dr. Shane Shapera will discuss the current state of diagnosis and treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)\, the challenges and benefits of existing therapies\, and the potential of Nerandomilast to revolutionize patient care. \n\n\n\nRegister now to learn about this new treatment on the horizon. \n\n\n\nDr. Shane Shapera\, Respirologist \n\n\n\nDr. Shane Shapera is an Associate Professor and Clinician Educator in the Faculty of Medicine at the University of Toronto. He is the Director of the Interstitial Lung Diseases (ILD) Program at Toronto General Hospital\, which is part of the University Health Network (UHN). He also works with the Toronto Lung Transplant Program\, providing pre-lung transplant assessments for patients with interstitial lung disease.  \n\n\n\nDr. Shapera has expertise in various aspects of ILD\, including idiopathic pulmonary fibrosis (IPF)\, systemic scleroderma interstitial lung disease (SSc-ILD)\, and myositis-associated lung disease. He has contributed to ILD research and care in Canada\, supported by the CPFF Robert Davidson Fellowship Program\, and has delivered numerous educational webinars on ILD-related topics.
URL:https://cpff.ca/event/nerandomilast-in-ipf-and-ppf-a-new-option-on-the-horizon/
CATEGORIES:Educational Forums
ATTACH;FMTTYPE=image/jpeg:https://cpff.ca/wp-content/uploads/2025/08/Nerandomilast_in_IPF_and_PPF_A_New_Option_On_the_Horizon_.jpg
END:VEVENT
END:VCALENDAR